Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D., will present at two June 2026 investor conferences focused on healthcare.

He will speak at the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Live webcasts and 60-day replays will be available on the company’s investor website.

News Market Reaction – MAZE

-1.14%

1 alert

-1.14% Session close to close

$1.38B Market Cap

0.0x Rel. Volume

In the May 27 session, MAZE declined 1.14%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:

• 2026 Jefferies Global Healthcare Conference in New York; presentation on Wednesday, June 3, 2026, at 3:45 p.m. ET
• Goldman Sachs 47^th Annual Global Healthcare Conference 2026; presentation on Wednesday, June 10, 2026, at 8:40 a.m. ET
  
  

Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

FAQ

When will Maze Therapeutics (MAZE) present at the 2026 Jefferies Global Healthcare Conference?

Maze Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 3:45 p.m. ET. According to Maze Therapeutics, this presentation will be accessible via live webcast on the Investors section of its website and archived for 60 days.

What time is Maze Therapeutics (MAZE) presenting at the 2026 Goldman Sachs Global Healthcare Conference?

Maze Therapeutics will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 10, 2026, at 8:40 a.m. ET. According to Maze Therapeutics, investors can access a live webcast and a 60-day archive via the company’s investor relations website.

How can investors watch Maze Therapeutics (MAZE) June 2026 conference webcasts?

Investors can watch Maze Therapeutics’ June 2026 conference presentations via live webcast on the company’s website, www.mazetx.com. According to Maze Therapeutics, the webcasts will appear in the Investors section and remain archived for on-demand viewing for 60 days after each event.

Who will represent Maze Therapeutics (MAZE) at the June 2026 investor conferences?

Chief executive officer Jason Coloma, Ph.D., will represent Maze Therapeutics at both June 2026 investor conferences. According to Maze Therapeutics, he will speak at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting the company’s kidney and metabolic disease programs.

What type of company is Maze Therapeutics (MAZE) presenting at these June 2026 conferences?

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. According to Maze Therapeutics, participating in the June 2026 Jefferies and Goldman Sachs healthcare conferences supports its outreach to investors interested in its pipeline and development strategy.